← Back to all trials
Recruiting
NCT07044297
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Sex: All
Ages: 16 Years – N/A
Healthy volunteers: Yes
Phase: PHASE3
Enrollment: 4390
Sponsor: Merck Sharp & Dohme LLC
Location: University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0006) Birmingham Alabama
Summary
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.
The goals of this study are to learn:
* If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day
* About the safety of MK-8527 and if people tolerate it
Eligibility Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results
* Is a cisgender man, transgender woman (assigned male sex at birth), transgender man (assigned female sex at birth), or gender nonbinary person
* Has had condomless receptive anal sex in the 12 months prior to screening (not including sex occurring in a mutually monogamous relationship) and has at least 1 of the following: receptive anal sex with 2 or more partners in the 3 months prior to screening (regardless of condom use), rectal or urethral gonorrhea or chlamydia or incident syphilis in the 6 months prior to screening, or any self-reported stimulant drug use with sex in the 3 months prior to screening
* Weighs ≥35 kg
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* Has hypersensitivity or other contraindication to any component of the study interventions
* Has evidence of acute or chronic hepatitis B infection
* Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ anal or cervical cancers
* Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
* Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
* Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1
* Is expecting to donate eggs at any time during the study
Source: ClinicalTrials.gov (NCT07044297). StuddyBuddy aggregates publicly available trial information.